Intersect ENT, Inc
XENT
XENT was delisted on the 12th of May, 2022.
160 hedge funds and large institutions have $1.03B invested in Intersect ENT, Inc in 2018 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 67 increasing their positions, 50 reducing their positions, and 26 closing their positions.
82% more call options, than puts
Call options by funds: $6.19M | Put options by funds: $3.41M
34% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 50
2% less capital invested
Capital invested by funds: $1.05B → $1.03B (-$17.1M)
7% less funds holding
Funds holding: 172 → 160 (-12)
42% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 26
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$31.6M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$18.1M |
| 3 |
O
OppenheimerFunds
New York
|
+$15.7M |
| 4 |
BlackRock
New York
|
+$14.6M |
| 5 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$13.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$20.1M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$19.6M |
| 3 |
Jennison Associates
New York
|
-$14.2M |
| 4 |
Millennium Management
New York
|
-$9.32M |
| 5 |
Neuberger Berman Group
New York
|
-$8.86M |
XENT Hedge Fund Activity: Q2 2018 in Review
160 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Intersect ENT, Inc (XENT) for Q2 2018, worth a combined $1.03B — down 1.6% from $1.05B a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of XENT and 15 opened new positions — a net loss of 11 holders — while 50 trimmed existing stakes and 67 added.
The largest buyer was HealthCor Management, adding an estimated $31.6M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $20.1M sold.
- 160 institutional investors held Intersect ENT, Inc (XENT) as of Q2 2018, down from 172 in Q1 2018.
- Funds reported $1.03B of Intersect ENT, Inc stock for Q2 2018, down 1.6% quarter-over-quarter.
- 15 funds opened new Intersect ENT, Inc positions in Q2 2018 and 26 closed out, a net change of -11 holders.
- The largest Intersect ENT, Inc buyer in Q2 2018 was HealthCor Management, an estimated $31.6M added.
- The largest Intersect ENT, Inc seller in Q2 2018 was Point72 Asset Management, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2018.